Pharmacological modulation of transglutaminase 2 in the unilateral ureteral obstruction mouse model
Open Access
- 5 October 2024
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 984, 177037
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk Foundation (NNF20OC0065767)
- Erik Hørslev and Birgit Hørslev Fund
- Aarhus Universitet
- Aarhus University Research Foundation (AUFF-F-2018-7-2)
This publication has 54 references indexed in Scilit:
- Transglutaminase 2 as a novel target in chronic kidney disease – Methods, mechanisms and pharmacological inhibitionPharmacology & Therapeutics, 2021
- A systematic approach to quantitative Western blot analysisAnalytical Biochemistry, 2020
- Tissue transglutaminase in fibrosis — more than an extracellular matrix cross-linkerCurrent Opinion in Biomedical Engineering, 2019
- Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse obstructed kidney: Special references to HIF-1 dependent gene expression of profibrogenic moleculesJournal of Pharmacological Sciences, 2018
- Transglutaminase 2 up-regulation is associated with RANKL/OPG pathway in cultured HPDL cells and THP-1-differentiated macrophagesAmino Acids, 2015
- Urinary transglutaminase 2 as a potential biomarker of chronic kidney disease detection and progressionThe Lancet, 2013
- Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-κB activationBiochemical and Biophysical Research Communications, 2010
- Degradation of transglutaminase 2 by calcium‐mediated ubiquitination responding to high oxidative stressFEBS Letters, 2009
- Tissue transglutaminase in normal and abnormal wound healing: Review articleAmino Acids, 2004
- Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity.Journal of Biological Chemistry, 1987